A Biomarker-driven Therapeutic Strategy for Esophageal Cancer Chemoradiotherapy in Patients With Resectable Adenocarcinoma of the ESophagus and Esophagogastric Junction

Author(s):  
Cancer ◽  
2000 ◽  
Vol 88 (11) ◽  
pp. 2429-2437 ◽  
Author(s):  
Johanna W. van Sandick ◽  
J. Jan B. van Lanschot ◽  
Fiebo J. W. ten Kate ◽  
G. Johan A. Offerhaus ◽  
Paul Fockens ◽  
...  

1994 ◽  
Vol 5 (4) ◽  
pp. 333-340 ◽  
Author(s):  
Linda Morris Brown ◽  
Debra T. Silverman ◽  
Linda M. Pottern ◽  
Janet B. Schoenberg ◽  
Raymond S. Greenberg ◽  
...  

2021 ◽  
Author(s):  
Wenjie Ni ◽  
Li-li Sun ◽  
Tong Fang

Abstract Background A citation classic is a highly cited work in a field and regarded as an influential contribution to the field’s advancements and literature. Analyzing citation classics and top articles promotes the recognition of research trends within a field. We present the results of the first analysis to identify the 100 most frequently cited research studies on esophageal cancer or esophagogastric junction cancer using the bibliometric analysis method. Method We searched the Web of Science on September 24, 2020. Articles were listed in descending order by the total number of citations, and the top-100 most-cited original articles on esophageal cancer or esophagogastric junction cancer were extracted and evaluated. Results The top-100 citation classics in esophageal cancer were published from 1981 to 2018. A significant increase was found in the number of citation classics from the early 1990s to the late 2000s, which was paralleled by an increase in randomized controlled trials focusing on the clinical treatment of tumors. The medians of the total and annual citations in our analysis were 444.50 (interquartile range [IQR] 346.25-684.50) and 30.08 (IQR 19.10-56.60), respectively. The majority of articles were published in the Journal of Clinical Oncology (n=26), originated in the United States (n=38) and focused on clinical therapies (n=59). The median impact factor of the journals was 27.603 (IQR 9.727-32.956). Conclusion Our analysis provides a historical perspective on the scientific progress of esophageal cancer and contributes to the recognition of important advances in this specialty.


2018 ◽  
pp. 24-27
Author(s):  
V. V. Tsukanov ◽  
A. V. Vasyutin ◽  
N. N. Butorin ◽  
Yu. L. Tonkikh ◽  
O. V. Peretyatko ◽  
...  

The article analyzes the prevalence and principles in treatment of Barrett’s esophagus. The prevalence of Barrett’s esophagus varies widely from region to region of the world and has ethnic differences. The use of endoscopic methods and the histological examination of the biopsies of esophageal mucosa are of utmost importance in the diagnosis of this pathology. The prevention of esophageal cancer is the main task in managing patients with Barrett’s esophagus. The length of the Barrett’s esophagus segment, the presence and extent of dysplasia is of the greatest importance to select tactics for managing patients. Endoscopic methods are widely used for the eradication of metaplasia sites, among which the radiofrequency ablation is the most effective one. Prolonged treatment with proton pump inhibitors is safe and reduces the risk of transformation of Barrett’s esophagus into adenocarcinoma of the esophagus. There is evidence that small doses of aspirin, nonsteroidal anti-inflammatory drugs, statins and ursodeoxycholic acid have the preventive effect on the development of esophageal cancer. However, the possibilities of using these drugs for this purpose are still limited. Anti-reflux surgery still holds relevance, but at the same time, it has no advantages over the drug therapy for the prevention of esophageal cancer.


Sign in / Sign up

Export Citation Format

Share Document